PROBLEM TO BE SOLVED: To provide improved agents and methods for treatment of diseases associated with β amyloid (Aβ).SOLUTION: Preferred agents include antibodies, e.g., humanized antibodies specific for β amyloid protein (Aβ). More specifically, the agents includes a monoclonal immunoglobulin effective at binding Aβ (e.g., binding soluble and/or aggregated Aβ), mediating phagocytosis (e.g., of aggregated Aβ), reducing plaque burden, reducing neuritic dystrophy and/or improving cognition (e.g., in a subject).
HUMANIZED AMYLOID β ANTIBODY FOR USE IN IMPROVING COGNITION